ALXO News and Press, ALX Oncology Holdings Inc.

Strengthens Leadership with Veteran Executives with Decades of Industry Experience Scott Garland Succeeds Co-Founder Corey Goodman, Ph.D., After More Than a Decade of Foundational Leadership SOUTH SAN FRANCISCO, Calif., June 30, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. ("ALX Onc...

2026-06-23 13:53:12 ET Topline Summary and Update I haven't had a formal look at ALX Oncology ( ALXO ), I was finally starting to feel like the company's investment thesis was starting to reach a point where a buy made sense, given that important data updates were anticipated at...

2026-06-01 13:23:59 ET Image source: The Motley Fool. Friday, May 8, 2026 at 8:30 a.m. ET Need a quote from a Motley Fool analyst? Email pr@fool.com Continue reading

SOUTH SAN FRANCISCO, Calif., June 01, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. ("ALX Oncology” Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients’ lives, today announced that ALX Oncol...

2026-05-09 04:02:52 ET More on ALX Oncology ALX Oncology Holdings Inc. (ALXO) Q1 2026 Earnings Call Transcript ALX Oncology Holdings Inc. 2026 Q1 - Results - Earnings Call Presentation ALX Oncology: Evorpacept For ASPEN-09 Presses On With 2 Key Milestones ALX...

2026-05-09 04:01:57 ET ALX Oncology Holdings Inc. (ALXO) Q1 2026 Earnings Call May 8, 2026 8:30 AM EDT Company Participants Jason Lettmann - CEO & Director Barbara Klencke - Chief Medical Officer Conference Call Participants Sara Hurvitz Kaiyu...

2026-05-08 08:21:48 ET More on ALX Oncology ALX Oncology: Evorpacept For ASPEN-09 Presses On With 2 Key Milestones ALX Oncology Holdings Inc. (ALXO) Q4 2025 Earnings Call Transcript ALX Oncology outlines pivotal trial readiness by end of 2026 with expanded ASPEN-09 s...

- Data from Phase 1b/2 trial of evorpacept + zanidatamab presented at ESMO Breast Cancer 2026 showed all patients with confirmed HER2-positive disease and high CD47 expression experienced durable responses to this combination - - Evorpacept data from two independent HER2-positive trials str...

- Data from Phase 1b/2 trial presented at ESMO Breast Cancer 2026 further validate a biomarker-driven development strategy for evorpacept - - Findings are consistent with previous results from the randomized ASPEN-06 trial in HER2-positive gastric cancer, which indicated CD47 expression...

- Company Will Discuss Data and Report First Quarter 2026 Financial Results on May 8 - SOUTH SAN FRANCISCO, Calif., April 30, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. ("ALX Oncology"; Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies desig...